Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.39 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26394056 | 0.91 | GPR119 (0.45) | GPR119USP30DPP4CACNB4CACNA1A | |
| SCHEMBL27105204 | 0.89 | GPR119 (0.47) | GPR119USP30NR1H2DPP4HDAC1 | |
| SCHEMBL22265869 | 0.87 | USP30 (0.46) | GPR119USP30NR1H2HDAC1HDAC2 | |
| SCHEMBL17839121 | 0.87 | GPR119 (0.48) | GPR119USP30NR1H2DPP4HDAC1 | |
| SCHEMBL22266021 | 0.86 | GPR119 (0.55) | GPR119USP30DPP4CACNB4CACNA1A | |
| SCHEMBL31312460 | 0.86 | GPR119 (0.55) | GPR119USP30DPP4CACNB4CACNA1A | |
| SCHEMBL22817815 | 0.86 | USP30 (0.43) | GPR119USP30NR1H2DPP4HDAC1 | |
| SCHEMBL28911357 | 0.85 | USP30 (0.45) | GPR119USP30NR1H2RORCCACNB4 | |
| SCHEMBL22031564 | 0.83 | GPR119 (0.53) | GPR119USP30HDAC1HDAC2RORC | |
| SCHEMBL22817830 | 0.83 | GPR119 (0.43) | GPR119USP30HDAC1HDAC2CACNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780827-B2 | Substituted 3-phenoxyazetidin-1-yl-pyrazines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-10 | — | — | US | disclosed |
| US-11780827-B2 | Substituted 3-phenoxyazetidin-1-yl-pyrazines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-10 | — | — | US | disclosed |
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| CN-109963834-B | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2023-04-14 | — | — | CN | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| EP-3541784-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | SLC18A1, CHRM1, CHRM2 | GPR119 55/4885USP30 1863/4885NR1H2 1504/4885 |
| US-11780827-B2 | Substituted 3-phenoxyazetidin-1-yl-pyrazines | GPR52, GPR88, GPR65 | GPR119 30/4885USP30 2386/4885NR1H2 150/4885 |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | GPR52, GPR88, GPR68 | GPR119 46/4885USP30 2559/4885NR1H2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.